ERAS — Erasca Inc. stock price and chart

Share this page

ERAS

$13.39-9.95%

as of close, Oct 16, 2026

☾ AH $13.39 -9.95%

Erasca Inc.Stock · HealthcareRussell 2000 0.1%Nasdaq Composite 0.009%US Stock Market 0.007%Russell 3000 0.004%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Jul 20, 2021

VolumeEEEE

20212022202420252026

2.04.06.08.010.012.014.016.018.020.022.0050.0M$13.39

2026-10-16

Price$13.39

MA20$16.50

MA50$15.81

Vol20.3M

What would $1,000 invested in ERAS be worth today? →

ERAS returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $13.39
YTD price return: +259.95%
YTD total return: +259.95%
Next earnings: Nov 11, 2026
Market cap: 4.7B2021-09 2.6B2026-10 4.7B+82.0% over the window
Enterprise value: 4.3B
Shares outstanding: 349.8M2020-12 21.9M2026-06 349.8M+1495.4% over the window
52W low: $2.11
52W high: $24.28
From 52W high: -44.85%
From 52W low: +536.10%
52W range: 51%

Volume

Rel volume: 1.35×
30D volume: 5.3M
30D $ vol: 79.1M

Fundamentals

EPS (ttm): -$0.972021-12 -$1.852026-06 -$0.97-47.5% over the window
FCF (ttm): -98.1M2020-12 -33.6M2026-06 -98.1M+191.6% over the window
FCF/share: -$0.282020-12 -$1.532026-06 -$0.28-81.7% over the window
Book value/share: $1.032020-12 -$5.202026-06 $1.03-119.9% over the window
ROE: -79.37%2021-12 -26.9%2026-06 -79.4%+195.2% over the window
ROA: -66.02%2020-12 -81.4%2026-06 -66.0%-18.9% over the window
Current ratio: 8.292020-12 8.772026-06 8.29-5.4% over the window

Growth (CAGR, ttm) · 10Y

Shares: +23.32%2025-06-30 → 2026-06-30283.7M → 349.8M (+23.3% total)+32.29%2023-06-30 → 2026-06-30151M → 349.8M (+131.6% total)+23.61%2021-06-30 → 2026-06-30121.2M → 349.8M (+188.5% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Book value/share: -21.17%2025-06-30 → 2026-06-30$1.31 → $1.03 (-21.2% total)-24.47%2023-06-30 → 2026-06-30$2.40 → $1.03 (-56.9% total)n/an/a
Price: +429.85%2025-10-16 → 2026-10-16$2.53 → $13.39 (+429.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+80.13%2023-10-16 → 2026-10-16$2.29 → $13.39 (+484.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-5.53%2021-10-15 → 2026-10-16$17.80 → $13.39 (-24.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +429.85%2025-10-16 → 2026-10-16$2.53 → $13.39 (+429.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+80.13%2023-10-16 → 2026-10-16$2.29 → $13.39 (+484.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-5.53%2021-10-15 → 2026-10-16$17.80 → $13.39 (-24.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -13.8×2021-09 -25.312026-10 -16.31-35.6% over the window
Fwd P/E: -24.8×
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 12.9×2021-09 5.332026-10 12.94+142.9% over the window
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -2.09%2021-12 -4.8%2026-06 -1.5%-68.1% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 349.8M ÷ 283.7M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -23.32%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-23.32%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($360.3M). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -23.32%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-258.8M) ÷ today's market cap ($4.7B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: -5.52%2021-12 0.0%2026-06 -4.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-258.8M + TTM dividends $0) ÷ today's market cap ($4.7B). Same caveat as the cash buyback yield.: -5.52%2021-12 0.0%2026-06 -4.0%

Vs own 10Y history

P/B: 91st

Bar = where today’s multiple sits in ERAS’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-9.95%

-16.47%

-12.83%

-29.60%

YTD

+259.95%

+429.25%

-24.78%

Financial statements

Open full ERAS financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

ERAS — Erasca Inc. price, chart and key statistics